PE20091969A1 - ANTI-PirB ANTIBODIES - Google Patents

ANTI-PirB ANTIBODIES

Info

Publication number
PE20091969A1
PE20091969A1 PE2009000673A PE2009000673A PE20091969A1 PE 20091969 A1 PE20091969 A1 PE 20091969A1 PE 2009000673 A PE2009000673 A PE 2009000673A PE 2009000673 A PE2009000673 A PE 2009000673A PE 20091969 A1 PE20091969 A1 PE 20091969A1
Authority
PE
Peru
Prior art keywords
heavy chain
seq
pirb
antibody
group
Prior art date
Application number
PE2009000673A
Other languages
Spanish (es)
Inventor
Jasvinder Atwal
Marc Tessier-Lavigne
Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/208,883 external-priority patent/US20100047232A1/en
Priority claimed from US12/316,130 external-priority patent/US20090232794A1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20091969A1 publication Critical patent/PE20091969A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REFERIDA A UN ANTICUERPO ANTI-PirB AISLADO QUE SE UNE A UN EPITOPE PirB HUMANO SELECCIONADO DEL GRUPO QUE CONSISTE EN YW259.2, YW259.9 YW259.12. EL ANTICUERPO AISLADO COMPRENDE AL MENOS 1-3 SECUENCIAS DE LA REGION HIPERVARIABLE DE UNA CADENA PESADA SELECCIONADA DEL GRUPO QUE CONSISTE: CADENA PESADA DE YW259.2 (SEQ ID N0:4), CADENA PESADA DE YW259.9 (SEQ ID N0:5) Y CADENA PESADA DE YW259.12 (SEQ ID N0:6). DICHO ANTICUERPO IMPIDE LA INHIBICION DEL CRECIMIENTO NEURITICO POR NOGO66 Y MIELINA UTIL EN EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVASREFERRING TO AN ISOLATED ANTI-PirB ANTIBODY JOINING A SELECTED HUMAN PirB EPITOPE FROM THE GROUP CONSISTING OF YW259.2, YW259.9 YW259.12. THE ISOLATED ANTIBODY INCLUDES AT LEAST 1-3 HYPERVARIABLE REGION SEQUENCES OF A SELECTED HEAVY CHAIN FROM THE GROUP CONSISTING: YW259.2 HEAVY CHAIN (SEQ ID N0: 4), YW259.9 HEAVY CHAIN (SEQ ID N0: 5 ) AND YW259.12 HEAVY CHAIN (SEQ ID N0: 6). SAID ANTIBODY PREVENTS THE INHIBITION OF NEURITIC GROWTH BY NOGO66 AND MYELIN USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

PE2009000673A 2008-05-13 2009-05-13 ANTI-PirB ANTIBODIES PE20091969A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5294908P 2008-05-13 2008-05-13
US12/208,883 US20100047232A1 (en) 2006-11-14 2008-09-11 Modulators of neuronal regeneration
US12/316,130 US20090232794A1 (en) 2007-12-11 2008-12-09 Modulators of neuronal regeneration

Publications (1)

Publication Number Publication Date
PE20091969A1 true PE20091969A1 (en) 2010-01-15

Family

ID=41319035

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000673A PE20091969A1 (en) 2008-05-13 2009-05-13 ANTI-PirB ANTIBODIES

Country Status (15)

Country Link
EP (1) EP2291405A1 (en)
JP (1) JP2011523359A (en)
KR (1) KR20110011676A (en)
CN (1) CN102089327A (en)
AR (1) AR071777A1 (en)
AU (1) AU2009246443A1 (en)
BR (1) BRPI0912769A2 (en)
CA (1) CA2723430A1 (en)
IL (1) IL209129A0 (en)
MX (1) MX2010012299A (en)
PE (1) PE20091969A1 (en)
RU (1) RU2010150754A (en)
TW (1) TW200950808A (en)
WO (1) WO2009140361A1 (en)
ZA (1) ZA201007976B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2787783A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
JP5947727B2 (en) 2010-01-20 2016-07-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Immunomodulation with anti-ILT5 antibodies and ILT5-binding antibody fragments
EP2838562B1 (en) * 2012-04-17 2017-08-30 Mayo Foundation for Medical Education and Research Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
CN103130898B (en) * 2013-01-28 2014-03-26 中国人民解放军第四军医大学 TAT-LBD-PEP fusion protein and application of TAT-LBD-PEP fusion protein in treatment of central nervous system lesion
JP7391868B2 (en) 2017-12-22 2023-12-05 ジョウンセ セラピューティクス， インク． Antibody against LILRB2
CN113056483A (en) 2018-07-09 2021-06-29 戊瑞治疗有限公司 Antibodies binding to ILT4
CN109439661B (en) * 2018-10-22 2020-10-23 西安医学院 Short hairpin shRNA (short hairpin ribonucleic acid), lentivirus and application thereof for inhibiting pirB expression
EP4143229A1 (en) 2020-05-01 2023-03-08 NGM Biopharmaceuticals, Inc. Ilt-binding agents and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003041650A2 (en) * 2001-11-14 2003-05-22 Immunex Corporation Modulation of lir function to treat rheumatoid arthritis
EP1981522B1 (en) * 2006-01-23 2012-09-12 President and Fellows of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration

Also Published As

Publication number Publication date
KR20110011676A (en) 2011-02-08
TW200950808A (en) 2009-12-16
AU2009246443A1 (en) 2009-11-19
CA2723430A1 (en) 2009-11-19
RU2010150754A (en) 2012-06-20
JP2011523359A (en) 2011-08-11
ZA201007976B (en) 2012-02-29
CN102089327A (en) 2011-06-08
EP2291405A1 (en) 2011-03-09
MX2010012299A (en) 2010-12-06
BRPI0912769A2 (en) 2015-10-13
WO2009140361A1 (en) 2009-11-19
AR071777A1 (en) 2010-07-14
IL209129A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
PE20091969A1 (en) ANTI-PirB ANTIBODIES
AR122771A2 (en) ANTIBODIES FOR THE TREATMENT OF CANCER, CONJUGATED, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID AND HOST CELL
PE20140806A1 (en) HUMANIZED ANTI-FACTOR D ANTIBODIES AND THEIR USES
PE20210115A1 (en) ANTI-TAU ANTIBODIES AND USE OF THEM
AR124676A2 (en) PHARMACEUTICAL FORMULATION COMPRISING A BIOPHARMACEUTICAL DRUG
AR077016A1 (en) USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES
PE20131403A1 (en) ANTI-OX40 ANTIBODIES AND METHODS OF USING THEM
PE20110382A1 (en) TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASE
ES2685823T3 (en) Anti-CD40 antagonist antibodies
CY1116488T1 (en) ANTI-PERPETIN antibodies
ES2667568T3 (en) Anti-B7-H3 antibody
AR096895A2 (en) ANTIBODY THAT Binds TO THE CYTOQUINE, THYMPIC STROMAL LYMPHOPOYETIN (TSLP)
UA118332C2 (en) Cs27l antigen binding proteins
UY33407A (en) SPECIFIC ANTIBODIES OF THE HUMAN GDF8 FACTOR
PE20120429A1 (en) MYOSTATIN BINDING PROTEINS
PE20080035A1 (en) HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR TYPE KINASE-1
PE20130817A1 (en) PEPTIDE ANTIBODIES BETA AMYLOID ANTI-N3PGLU AND USES THEREOF
ES2670621T3 (en) Antibodies that bind to OX40 and its uses
MX2009004532A (en) Compositions and methods for binding sphingosine-1-phosphate.
PE20141271A1 (en) T-CELL RECEPTOR TYPE ANTIBODIES SPECIFIC TO A WT1 PEPTIDE PRESENTED BY HLA-A2
AR075604A1 (en) ANTIBODIES AGAINST A LINK THAT INDUCES PROLIFERATION (APRIL)
RS54468B1 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
AR091702A1 (en) ANTI-CD79B ANTIBODIES AND IMMUNOCATE PLAYERS
PE20110797A1 (en) ANTI MN ANTIBODIES
PE20120427A1 (en) ANTIBODIES AGAINST THE HUMAN CGRP RECEPTOR

Legal Events

Date Code Title Description
FD Application declared void or lapsed